Lakefront Biotherapeutics reported EUR2.31B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
argenx SE USD 8.07B 1.17B Jun/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
Genmab DKK 2.8B 228M Jun/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
GRIFOLS EUR 5.35B 40M Sep/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
Incyte USD 5.52B 505.2M Sep/2026
Merck EUR 15.14B 1.37B Sep/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 33.21B 1.68B Sep/2026
UCB EUR 6.05B 733M Dec/2025
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026